A lung-fibrosis drug missed its trial goal. Syndax does not plan to develop it further.
Syndax Pharmaceuticals (SNDX) announced that its Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet the primary endpoint of reducing lung function decline. The drug was well tolerated but will not be developed further for IPF. Ongoing trials in chronic graft-versus-host disease (cGVHD) continue, with results expected later this year and in early 2028. The company remains focused on advancing axatilimab and revumenib in other indications.
How this was made
The 30-second read
Why it matters
The trial miss reduces near‑term revenue expectations from IPF and may lower the company's valuation multiples.
Market read
Syndax (SNDX) faces a likely short‑term price decline due to the failed IPF trial, while its cGVHD program remains a potential upside.
What to watch
Syndax's pipeline includes other late‑stage programs and a cash position that may support the stock despite this miss.
Background
Syndax's axatilimab is FDA‑approved for chronic graft‑versus‑host disease; the company is shifting focus to that indication after the IPF failure.
Ticker impact
Syndax announced its Phase 2 MAXPIRe trial in IPF missed the primary endpoint and will not pursue further development in this indication.
downward pressure as the market prices in the failed trial outcome
Biotech stocks react sharply to trial outcomes; a missed primary endpoint in a sizable Phase 2 study typically triggers a sell‑off.
Market effects
May dampen sentiment for other IPF and fibrosis drug developers, potentially affecting peer valuations.
Primarily impacts US biotech sector; limited broader market effect.
Limited to biotech investors; no macro impact.
Counterpoint
The drug continues to show promise in cGVHD, which could offset the IPF setback if later data are strong.
Key entities
- ExecutiveNick Botwood
Head of R&D and CMO who commented on the trial outcome.
- ExecutiveMichael A. Metzger
CEO who discussed the company's pipeline focus.
